compani
creat bluematrix
sale ep estim primarili
messag ep beat consensu estim
boost sale beat forecast
factset consensu growth asset trulic taltz
emgal beat est oper margin beat forecast bp vs
estim ep upsid boost higher incom
vs estim lower tax rate vs expect
maintain margin guidanc increas ep non-gaap
rang maintain neutral rate
earn confer call detail underway morn thursday april
edt dial passcod webcast link
detail robust sale beat driven strong underli demand higher
demand pull due pandem report ep
beat estim consensu sale y/i beat
estim consensu product trulic
type diabet product taltz psoriasi emgal cgrp migrain
estim along higher sale alimta cymbalta vs expect
see figur varianc tabl sale estim
quarter estim gross net trulic
monthli price net price sequenti worsen
effect manag gross margin consensu
forecast sg aggreg effect
manag beat estim bp oper margin increas y/i
forecast oper incom beat estim
consensu increas incom vs
estim primarili higher net gain invest secur partial off-set
lower interest incom quarter lower-than-expect tax rate vs
estim also boost ep
ep guidanc see figur line consensu estim
ep guidanc increas revenu guidanc
maintain sg guidanc maintain see figur
chang gross margin guidanc non-gaap basi oper
incom margin maintain tax rate guidanc maintain along
guidanc increas incom expens
page analyst certif import disclosur
compani data guggenheim secur llc estim factset
catalyst gener back-end-load clinic catalyst like
modest impact stock
jardianc emperor-hfref top-line result may come
primari complet date pcd emperor-hfpef late key
data readout azn farxiga shown posit result hfref popul
dapa-hf result see note practice-chang data azn farxiga
remain optimist mirikizumab upcom phase readout psoriasi
oasi primari complet date pcd per clinicaltri gov look
updat ibd trial updat ulcer coliti lucent pcd
crohn diseas delay due
page analyst certif import disclosur
line itemsa dec estsfactset consensu est total sale sale growth changeno changeno income/ expens changeno ep changeno guggenheim secur llc estim compani report pipelin potenti catalystsag moa indicationtrialpotenti catalyststock impactour viewtimingmirikizumab anti inhibitor psoriasisphas oasi result middl inhibitor heart failur -hfrefphas emperor-reducedtop-lin inhibitor ulcer colitisphas lucent receptor type diabetesphas inhibitor heart failur -hfpefphas emperor-preservedtop-lin result late inhibitor alopecia areata sever severephas result late btk inhibitor previous treat chronic lymphocyt lymphoma cll /sllphase i/ii -bruinaddit impactmarket viewpositivenegativemagnitud pipelin potenti catalyst pcd primarycompletiondateasperclinicaltri gov global
page analyst certif import disclosur
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst whose name appear report receiv compens base upon variou factor includ qualiti research
investor client feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc affili expect receiv intend seek compens invest bank servic
compani next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori compani
creat bluematrix
buy describ stock expect provid total return price appreci plu yield within period
neutral describ stock expect provid total return price appreci plu yield plu minu within
sell describ stock expect provid total neg return price appreci plu yield within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/or
cs coverag suspend guggenheim secur llc suspend coverag compani
nc cover guggenheim secur llc cover compani
monitor describ stock whose compani fundament financi monitor financi project opinion
invest merit compani provid
review ur follow releas signific news compani rate temporarili place review suffici
inform obtain assess analyst
guggenheim secur llc methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ restrict analys
market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash flow ev/ebitda price-to-earnings pe/growth
price-to-cf p/fcf premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
price target assign buy- sell-rat stock price target neutral-r stock provid discret analyst
page analyst certif import disclosur
